Orchid Pharma Limited (ORCHPHARMA) reports strong Q2 FY27 results with a 148% surge in EBITDA, highlighting the success of its 'Soil to VialFROM' initiative.
Gujarat Themis Biosyn Limited (GUJTHEM) announces acquisition of MicroBiopharm Japan, enhancing its fermentation capabilities and expanding its CDMO services.
Dishman Carbogen Amcis Limited (NSE: DCAL) reports Q2FY27 results with a 22.8% YoY revenue decline, driven by lower CDMO segment revenue.
Balaxi Pharmaceuticals Limited (NSE: BALAXI) reports strong Q2 & H1 FY27 results with revenue up 39% and PAT surging 450%.
Suven Life Sciences Limited (SUVEN) to present Masupirdine and Tenaclidine clinical data at CTAD-2026.
Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.
Themis Medicare Limited (THEMISMED) reports a 15% revenue increase in Q2 FY27, with EBITDA turning positive at 6.2% margin.